Portola Pharmaceuticals

South San Francisco,  CA 
United States
  • Booth: 1239

Portola Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa®(betrixaban) and Andexxa®[coagulation factor Xa (recombinant), inactivated-zhzo]. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for hematologic cancers.